Eden Research is an AIM Listed, Oxfordshire-based company focused on developing sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries.
The Company is currently the only UK-quoted company focused on biopesticides for sustainable agriculture and is well positioned to capitalise on the rapidly growing biopesticides market, which is projected to be worth over £11 billion by 2027.
The fundraising was launched via a Firm Capital Raising by the issue of 16,923,077 New Ordinary, Conditional Capital Raising by the issue of up to 144,615,385 New Ordinary Shares at 6.5 pence per share and Proposed Retail Offer of up to 7,692,308 New Ordinary Shares at 6.5 pence per share.
The net proceeds of the Firm Capital Raising and any proceeds of the Retail Offer will be used principally to fund materials to build up inventory for the new seed treatment. Subject to the satisfaction of the Conditions, the Conditional Capital Raising will be used to advance the development, registration and commercialisation of new key product categories, including new insecticide formulations and seed treatments, as well as to provide additional working capital for the Group associated with the new development areas.
For further information, click here.
Having helped Eden Research with the design and production of their annual report for the first time in June this year, the Perivan shareholder communications team was delighted to work with Cenkos Securities who acted as Nominated Adviser and Broker on the production of the documentation which was successfully completed and posted on 31st July 2023.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.